Jack Ahrens, Tomotaka (Tommy) Goji and Charles Immel to provide commercial and financial expertise and leadership
Of the recent additions, Alfred R. Berkley III, Chairman of the Board of Directors of Noxilizer, noted, “We are committed to recruiting talented leaders to our already outstanding board. Jack, Tommy and Chuck bring tremendous capital allocation, operational, and commercial experience and expertise to the table. I’m confident they will make enormous contributions as we support Lawrence Bruder and his team in commercializing NO2 sterilization technology.”
President and CEO of Noxilizer, Lawrence Bruder, emphasized, “Jack and Tommy provide relevant experience from their portfolio companies, while Chuck brings a hands-on perspective of leading a sterilization company, especially in operations, sales and marketing. We welcome them to the team to accelerate our progress.”
About Jack K, Ahrens, II:
Jack K. Ahrens, II – Jack is a founding General Partner of TGap Venture Capital Funds, headquartered in Kalamazoo, a Midwest focused venture capital fund that has raised over $46 million. Jack has been a venture capitalist since 1979; first as President of United Capital Corporation of Illinois (an SBIC), since 1983 as a General Partner of Pathfinder Venture Capital Funds I, II, and III. Prior to that he had seven years of experience in bank trust investments and operations. He has served on many Boards during his career including Afmedica, Inc., Central Data, Inc., Micro Business Applications, Inc., MedVantx, Inc., MinuteClinic, Inc., NeoChord, Inc., Rapid Diagnostek, Regenesis Biomedical and Vector General, Inc.
About Tomotaka (Tommy) Goji:
Tomotaka (Tommy) Goji is Managing Partner at UTEC (The University of Tokyo Edge Capital), a Tokyo-based seed/early stage focused venture capital firm. Since he co-founded UTEC in 2004, he has raised three UTEC funds totaling approximately $300 million, which achieved nine IPO and seven M&A exits as of today. Prior to UTEC, he worked for Japan’s Ministry of Economy, Trade and Industry (METI), where he drafted “The Limited Partnership Act for Venture Capital Investment,” an enactment for Japan’s private equity/venture capital funds. His portfolio companies where he served on board include: Tella (immunology, listed on Tokyo Stock Exchange JASDAQ), Morpho (digital image processing, listed on Tokyo Stock Exchange Mothers), and SAIAN Corporation (nitrogen dioxide sterilization, merged by Noxilizer in 2013).Tommy graduated from the University of Tokyo’s Faculty of Law and Stanford University’s Graduate School of Business.
About Charles Immel:
Charles Immel is an independent healthcare industry advisor with broad global experience in medical devices and biopharmaceuticals. He has served most recently in executive leadership roles in Gambro, a large European manufacturer of renal therapy products recently acquired by Baxter Healthcare Corporation. Chuck was President of the Healthcare Division of STERIS Corporation, a leading global provider of medical devices in infection prevention and surgical environments. He started his career with Baxter Healthcare Corporation in the Biosciences Division where he held a variety of commercial leadership roles in North America, Europe and Japan. During his career he has launched numerous successful new products and services in the healthcare market by focusing on solutions that improve the efficacy and safety of care, while addressing overall system cost. He is a former member of BioOhio (Board of Trustees and Executive Committee), AdvaMed, American Chamber of Commerce Japan and Plasma Protein Therapeutics Association (Operations Committee). He is a graduate of The Ohio State University.
About Noxilizer, Inc.:
Noxilizer, Inc. provides a unique, room temperature nitrogen dioxide sterilization technology that offers many benefits over traditional sterilization methods. Noxilizer sells sterilization and decontamination equipment to pharmaceutical, biotech and medical device manufacturers and also offers contract sterilization services at its Baltimore, MD headquarters. Noxilizer’s expert microbiology and material compatibility team is ready to partner to solve sterilization challenges through every phase of the process.
Noxilizer, Inc., founded in 2004, is privately held with offices in the US, United Kingdom, and Japan.
C (574) 304-1502